Panitumumab: Interim Phase II data

Interim data from stage-one of an open-label Phase II trial in 19 evaluable patients

Read the full 141 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE